NASDAQ · NVCR
NovoCure Limited
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarThe next earnings date for NVCR has not been announced yet.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.21 | $-0.14 | $-0.31 | 4 |
| Dec 2026 | $-0.22 | $-0.15 | $-0.31 | 4 |
| Mar 2027 | $-0.20 | $-0.12 | $-0.27 | 2 |
| Jun 2027 | $-0.16 | $-0.09 | $-0.23 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
The Motley Fool · Fintel · RTTNews · Zacks- The Motley Fool · 34 min agoNovoCure (NVCR) Q3 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- Fintel · 3 h agoNovoCure Limited Reports Third Quarter 2026 Financial Results and Raises 2026 GuidanceNovoCure Limited reported its financial results for the third quarter ended September 30, 2026, featuring total net revenues of $193.4 million, representing an increase of 16% compared to the same period in 2025. This revenue growth was primarily driven by a 19% increase in globa
- RTTNews · 7 h agoNovoCure Q3 Loss Decreases(RTTNews) – NovoCure (NVCR) revealed Loss for third quarter of -$10.44 million
- Zacks · 7 h agoNovoCure (NVCR) Reports Q3 Loss, Tops Revenue EstimatesNovoCure (NVCR) delivered earnings and revenue surprises of +57.14% and +5.50%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
- MarketBeat · Sep 18, 10:02 AM EDTNovoCure Eyes Glioblastoma Growth, Cancer Launches and EBITDA Break-EvenNovoCure (NASDAQ:NVCR) outlined its strategy for returning its glioblastoma franchise to growth, expanding launches in pancreatic and lung cancer, and moving toward profitability during the Morgan Stanley Healthcare Conference. Chief Executive Officer Frank Leonard said the comp
- Zacks · Sep 7, 11:12 AM EDTNovocure Reports Patient Data Exposure in Cybersecurity IncidentNVCR says a cyber incident exposed limited patient and contact data, but devices stayed secure and operations remained fully functional.
- Zacks · Aug 28, 9:55 AM EDTWall Street Analysts See a 50.86% Upside in NovoCure (NVCR): Can the Stock Really Move This High?The average of price targets set by Wall Street analysts indicates a potential upside of 50.9% in NovoCure (NVCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- Zacks · Aug 20, 12:00 PM EDTAre You Looking for a Top Momentum Pick? Why NovoCure (NVCR) is a Great ChoiceDoes NovoCure (NVCR) have what it takes to be a top stock pick for momentum investors? Let's find out.
- Zacks · Aug 12, 9:55 AM EDTWall Street Analysts Think NovoCure (NVCR) Could Surge 53.68%: Read This Before Placing a BetThe average of price targets set by Wall Street analysts indicates a potential upside of 53.7% in NovoCure (NVCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- Zacks · Aug 7, 8:59 AM EDT4 Healthcare Stocks to Watch as Defensive Demand StrengthensHealthcare's defensive demand is strengthening in 2026. BTSG, HRMY, UNH and NVCR stand out on improving earnings outlooks and steady sector momentum.
- Zacks · Jul 27, 12:00 PM EDTNovoCure (NVCR) Upgraded to Buy: What Does It Mean for the Stock?NovoCure (NVCR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Zacks · Jul 27, 9:55 AM EDTWall Street Analysts Believe NovoCure (NVCR) Could Rally 46.63%: Here's is How to TradeThe mean of analysts' price targets for NovoCure (NVCR) points to a 46.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for NovoCure Limited from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.